Holder Update - MXCOE Listed Options

RNS Number : 0129K

MGC Pharmaceuticals Limited

27 August 2021

 

Holder Update - MXCOE Listed Options Expiring 31 August

27 August 2021

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to provide an update to all holders of MXCOE MGC options that they are due to expire next Tuesday 31 August 2021, at 5:00pm (AWST).  MXCOE have an exercise price of $0.045 per option.

The Company previously advised on 3 August 2021 that the MXCOE listed options would cease trading on the ASX on Wednesday 25 August 2021.  This has occurred and MXCOE are no longer tradeable on the ASX but can be exercised by the holder by completing the MXCOE exercise form.

The options which have an exercise price of $0.045 per option can still be exercised up until 5:00pm on Tuesday, 31 August 2021 (AWST) by lodging a "Notice of Exercise of Options" and payment of $0.045 per option exercised to the Company.

The options will expire at 5:00pm on Tuesday, 31 August 2021 (AWST) and option holders' right to subscribe for MGC Shares at $0.045 per share will lapse after this time.

As detailed in the Company's Announcement made on 3 August 2021, are instruction on how MXCOE option holders can exercise and pay before the deadline of 5:00pm on Tuesday, 31 August 2021 (AWST).

Further details on how to exercise your MXCOE options can also be found on MGC Pharma's website at the following location:

https://wcsecure.weblink.com.au/pdf/MXC/02402891.pdf  

-Ends-

Authorised for release by the Executive Chairman. For further information, please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [phone] [e-mail]	UK PR Advisors - Tavistock Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels :

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

MSCKZGZRNNFGMZG